TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28935227

Group type: EXPERIMENTAL
Intervention: Face-to-face 30-minute physiotherapy education and training session on pulmonary complications, early ambulation, and breathing exercises
Number of subjects: 29

Group type: COMPARATOR
Intervention: Information booklet about preventing pulmonary complications with early ambulation and breathing exercises
Number of subjects: 29
Study: 26586096

Group type: EXPERIMENTAL
Intervention: F1.8 formula (1.8 g protein/418.4 kJ)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: F2.7 formula (2.7 g protein/418.4 kJ)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: F1.8 formula
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: F2.7 formula
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: F1.8 and F2.7 formula
Number of subjects: 238

Group type: COMPARATOR
Intervention: Breast-fed group (reference)
Number of subjects: 238
Study: 24613908

Group type: EXPERIMENTAL
Intervention: Chemotherapy for at least 5 months
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Clinical Benefit Response (CBR)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Duration of CBR (n = 62)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Clinically meaningful improvements in PROs (n = 100-116)
Number of subjects: 311
Study: 22513706

Group type: EXPERIMENTAL
Intervention: Intermittent high-volume predilution on-line haemofiltration (HF)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard intermittent haemodialysis (HD)
Number of subjects: 273
Study: 20565206

Group type: EXPERIMENTAL
Intervention: Cued reaction time task with dual-response version (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Differential conditioning procedure (Experiments 2 and 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued reaction time task (Experiment 3)
Number of subjects: 0
Study: 17660174

Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional knot tying and electrocautery
Number of subjects: 80
Study: 16186005

Group type: EXPERIMENTAL
Intervention: Self-reported expressed anger (very low and very high)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Self-reported expressed anger
Number of subjects: 2
Study: 12030948

Group type: EXPERIMENTAL
Intervention: Red pepper powder (2.5 g/day for 5 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9914576

Group type: EXPERIMENTAL
Intervention: Crinone 4%
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Crinone 8%
Number of subjects: 127
Study: 7485681

Group type: EXPERIMENTAL
Intervention: Permethrin‐ and lambdacyhalothrin‐impregnated bed nets
Number of subjects: 35000

Group type: COMPARATOR
Intervention: Control communities (no bed nets)
Number of subjects: 35000
Study: 2258591

Group type: EXPERIMENTAL
Intervention: Iopamiron 370
Number of subjects: 50

Group type: COMPARATOR
Intervention: Telebrix Hystero
Number of subjects: 50
Study: 7294869

Group type: EXPERIMENTAL
Intervention: Thermal blanket
Number of subjects: 44

Group type: COMPARATOR
Intervention: Topical paraffin
Number of subjects: 44
Study: 31586540

Group type: EXPERIMENTAL
Intervention: VeCS technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cystoscopy
Number of subjects: 40
Study: 27306883

Group type: EXPERIMENTAL
Intervention: Parent Management Training-Oregon Model (PMTO)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Care As Usual (CAU)
Number of subjects: 146
Study: 26091023

Group type: EXPERIMENTAL
Intervention: 3% Hypertonic Saline (250 mL)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: 7.5% Hypertonic Saline (250 mL)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Lactated Ringer's Solution (LRS) (250 mL)
Number of subjects: 294
Study: 24597922

Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation Therapy (CST)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 22217183

Group type: EXPERIMENTAL
Intervention: Bothersome tinnitus patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 17
Study: 18987287

Group type: EXPERIMENTAL
Intervention: Resistance exercise (90-min free weight lifting session followed by a 6.5-h rest)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (60-min run followed by a 7-h rest)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (8-h rest)
Number of subjects: 11
Study: 15978753

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen 0.625 mg/day (CEE 0.625 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Continuous transdermal estradiol 50 microg/day (tE2)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen 0.625 mg/day plus medroxyprogesterone acetate 2.5 mg/day (CEE 0.625 mg/MPA 2.5 mg)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Oral 2 mg 17‐beta estradiol combined with 1 mg norethistrone acetate (E2/norethistrone)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 88
Study: 12975428

Group type: EXPERIMENTAL
Intervention: CCTGA patients (group A)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CCTGA patients (group B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 15
Study: 11764834

Group type: EXPERIMENTAL
Intervention: Wet bonding with OptiBond Solo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wet bonding with PermaQuick PQI
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wet bonding with Prime & Bond NT (one coat)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wet bonding with Prime & Bond NT (two coats)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Wet bonding with Prime & Bond 2.1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dry bonding with all materials
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wet bonding vs Dry bonding for each material
Number of subjects: 60
Study: 8665771

Group type: EXPERIMENTAL
Intervention: Active standing
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phase between IRP and blood pressure at 0.1 Hz
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phase between IRP and blood pressure at 0.25 Hz
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intra-arterial and IRP fluctuations
Number of subjects: 25
Study: 1893805

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (zinc sulfate 600 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6620373

Group type: EXPERIMENTAL
Intervention: Low-nicotine cigarette
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-nicotine cigarette
Number of subjects: 0

Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 0
Study: 30604577

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure therapy
Number of subjects: 177

Group type: COMPARATOR
Intervention: Previous stroke
Number of subjects: 177

Group type: COMPARATOR
Intervention: Adequate adherence at 1 month
Number of subjects: 177
Study: 29140378

Group type: COMPARATOR
Intervention: Implant-supported fixed prosthesis (group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Implant-supported fixed prosthesis (group 2)
Number of subjects: 20
Study: 25121397

Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway (LMA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 42
Study: 23245807

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mgqd)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Candesartan (16 mgqd)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dietary sodium intake and blood pressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glycemia and HbA1c
Number of subjects: 12
Study: 21281262

Group type: EXPERIMENTAL
Intervention: Volar locked plating (n = 33)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bridging external fixation
Number of subjects: 63
Study: 18156641

Group type: EXPERIMENTAL
Intervention: 5 mg of elemental iron/daily added to school meals (group A)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: 10 mg of elemental iron/daily added to school meals (group B)
Number of subjects: 728
Study: 17062141

Group type: EXPERIMENTAL
Intervention: Work style and physical activity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work style intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 0
Study: 14745877

Group type: EXPERIMENTAL
Intervention: HAI of 5‐FU
Number of subjects: 316

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 316
Study: 11682399

Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 30
Study: 9041597

Group type: EXPERIMENTAL
Intervention: Diphtheria‐tetanus toxoids with pertussis toxoid
Number of subjects: 3450

Group type: COMPARATOR
Intervention: Diphtheria‐tetanus toxoids without pertussis toxoid (Control)
Number of subjects: 3450
Study: 7929824

Group type: EXPERIMENTAL
Intervention: Insulin infusion at 21.5 pmol/kg per min for 2.5 h during hyperinsulinemic-euglycemic clamp
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control saline infusion (0.45% saline)
Number of subjects: 17
Study: 3345042

Group type: EXPERIMENTAL
Intervention: Allergen challenge
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline insufflation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Distilled water insufflation
Number of subjects: 7
Study: 29453433

Group type: EXPERIMENTAL
Intervention: Earlier Oral Feeding Group (initiated at 30 weeks' PMA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Later Oral Feeding Group (initiated at 33 weeks' PMA)
Number of subjects: 66
Study: 27317358

Group type: EXPERIMENTAL
Intervention: Featback (psychoeducation and fully automated self-monitoring and feedback system)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Featback supplemented with low-intensity (weekly) digital therapist support
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Featback supplemented with high-intensity (3 times a week) digital therapist support
Number of subjects: 354

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 354
Study: 24289887

Group type: EXPERIMENTAL
Intervention: rhEPO (40,000 IU intravenously, twice a week for 5 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 24341348

Group type: EXPERIMENTAL
Intervention: 10 days of inpatient rehabilitation followed by a 6-week hybrid home program
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care (a 6-week hybrid home program)
Number of subjects: 140
Study: 20206217

Group type: EXPERIMENTAL
Intervention: Dried plums
Number of subjects: 19

Group type: COMPARATOR
Intervention: Low-fat cookies
Number of subjects: 19
Study: 18427724

Group type: EXPERIMENTAL
Intervention: Alendronate 5 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Alfacalcidol 1.0 mug/day
Number of subjects: 33
Study: 16614713

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy with activities from 1000 to 6000 MBq
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: First course of radioiodine therapy
Number of subjects: 68
Study: 15143855

Group type: EXPERIMENTAL
Intervention: Patients with known exposure to molds
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Mold-exposed patients
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Healthy blood donor controls
Number of subjects: 1500
Study: 10856472

Group type: EXPERIMENTAL
Intervention: Pulsatile IV GnRH (10-20 microgram/90 min) after GnRH‐agonist down‐regulation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) (50-150 mg; cycle days 3-7)
Number of subjects: 28
Study: 9173664

Group type: EXPERIMENTAL
Intervention: Mannitol and low sodium solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Polyethylene glycol and high sodium concentration solution
Number of subjects: 32

Group type: COMPARATOR
Intervention: Polyethylene glycol and low sodium solution
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All three solutions
Number of subjects: 32
Study: 7516648

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 million KIU intravenously before cardiopulmonary bypass and 2 million KIU in the filling liquid of the bypass circuit)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 60
Study: 3031260

Group type: EXPERIMENTAL
Intervention: High phosphorus intake (1.67 mmol/kg/d, 50 mg/kg/d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Moderate phosphorus intake (1.34 mmol/kg/d, 40 mg/kg/d)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low phosphorus intake (1.01 mmol/kg/d, 30 mg/kg/d)
Number of subjects: 27
Study: 31529450

Group type: EXPERIMENTAL
Intervention: Betamethasone (BMZ)
Number of subjects: 2831

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2831
Study: 29108405

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 26598750

Group type: EXPERIMENTAL
Intervention: In-person counseling (n = 33)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Telephone counseling (n = 34)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (UC) (n = 33)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined weight loss intervention groups (in-person and telephone)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 100
Study: 24739318

Group type: EXPERIMENTAL
Intervention: 50 mg prednisone daily for 5 days
Number of subjects: 79

Group type: COMPARATOR
Intervention: Identical‐appearing placebo
Number of subjects: 79
Study: 22983930

Group type: EXPERIMENTAL
Intervention: Preoperative intervention (gait analysis and strength data collection)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Increased preoperative quadriceps strength
Number of subjects: 38

Group type: COMPARATOR
Intervention: No increase in preoperative quadriceps strength
Number of subjects: 38
Study: 19729663

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 5993

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5993
Study: 17313691

Group type: EXPERIMENTAL
Intervention: Esophageal Doppler-guided fluid management
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group (standard hemodynamic management)
Number of subjects: 162
Study: 14963484

Group type: EXPERIMENTAL
Intervention: anterior Greenbaum sub‐Tenon cannula
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: mid Kumar‐Dodds sub‐Tenon cannula
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: posterior Steven's sub‐Tenon cannula
Number of subjects: 150
Study: 11728657

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 84

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 84
Study: 9539190

Group type: EXPERIMENTAL
Intervention: Indole‐3-carbinol (13C), 400 mg for two months
Number of subjects: 5
Study: 7961534

Group type: EXPERIMENTAL
Intervention: Behavior therapy (exposure in vivo and response prevention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturalistic behavior therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homework exposure and response prevention
Number of subjects: 0
Study: 2628523

Group type: EXPERIMENTAL
Intervention: Passive motion palpation protocol
Number of subjects: 60
Study: 1173830

Group type: EXPERIMENTAL
Intervention: Follow-up care intervention group (assigned by a follow-up clerk)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (standard follow-up)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Follow-up care intervention group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 31821098

Group type: EXPERIMENTAL
Intervention: Oxybutynin (0.2 mg/kg 3 times daily)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 49
Study: 31165710

Group type: EXPERIMENTAL
Intervention: Immediate treatment group (ITG) - Big White Wall (BWW) intervention for 3 months
Number of subjects: 812

Group type: COMPARATOR
Intervention: Delayed treatment group (DTG) - no intervention for 3 months
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Higher BWW user groups
Number of subjects: 812
Study: 28825957

Group type: EXPERIMENTAL
Intervention: Tranilast 8% liposomal gel
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (tranilast‐free liposomal gel)
Number of subjects: 26
Study: 26093951

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chronotherapy (administered at 18:00)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chronotherapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cisplatin administered at 18:00
Number of subjects: 41
Study: 24282565

Group type: EXPERIMENTAL
Intervention: Mobile Teams (MTs) providing counseling, condoms, screening and treatment for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and Trichomonas vaginalis (TV) infections; presumptive metronidazole treatment.
Number of subjects: 24814

Group type: COMPARATOR
Intervention: Control cities (matched control group)
Number of subjects: 24814
Study: 21539680

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg daily
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Tiotropium
Number of subjects: 362
Study: 18997675

Group type: EXPERIMENTAL
Intervention: BUP (300 mg) + NAL (50 mg)
Number of subjects: 0
Study: 22240178

Group type: EXPERIMENTAL
Intervention: E₂V/DNG
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 15943843

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12637255

Group type: EXPERIMENTAL
Intervention: Nandrolone (600 mg/wk) + Resistance Training (RT)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Nandrolone (600 mg/wk)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Oxandrolone (20 mg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Oxandrolone (20 mg/day) + Placebo
Number of subjects: 2
Study: 10539752

Group type: EXPERIMENTAL
Intervention: 10 microgram Se as L-selenomethionine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 20 microgram Se as L-selenomethionine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 30 microgram Se as L-selenomethionine
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 40 microgram Se as L-selenomethionine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 7484820

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study: 2186982

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 6893252

Group type: EXPERIMENTAL
Intervention: Composite meals with chicken protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite meals with beef protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite meals with soybean protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite meals with increased calcium content (milk added to soybean meal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite meals with total zinc content
Number of subjects: 0
Study: 31568796

Group type: EXPERIMENTAL
Intervention: One 6-nmol intradermal injection every 2 weeks for 14 weeks
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 29664339

Group type: EXPERIMENTAL
Intervention: MR imaging (n = 179) within 2 weeks after injury
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care (n = 177; MR imaging not performed)
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: MR imaging (n = 179)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual care (n = 177)
Number of subjects: 356
Study: 28245835

Group type: EXPERIMENTAL
Intervention: Facilitation of creams availability and continuous electronic monitoring of consumption with regular feedback on skin care performance.
Number of subjects: 504

Group type: COMPARATOR
Intervention: Basic education on skin protection (as 'care as usual').
Number of subjects: 504
Study: 25840779

Group type: EXPERIMENTAL
Intervention: Printed Decision Support (PDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer Decision Support (CDS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 23954997

Group type: EXPERIMENTAL
Intervention: Immune tolerance group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Inactive hepatitis B surface antigen carriers group
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resolved hepatitis B group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 20457158

Group type: EXPERIMENTAL
Intervention: Omentectomy plus Roux-en-Y gastric bypass (RYGB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Omentectomy alone
Number of subjects: 29
Study: 17940809

Group type: EXPERIMENTAL
Intervention: Nadroparin (2,850/3,800 U daily subcutaneous)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study: 16645445

Group type: EXPERIMENTAL
Intervention: Mild hypercapnia (end‐tidal carbon dioxide tension 50 mmHg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normocapnia (end‐tidal carbon dioxide tension 35 mmHg)
Number of subjects: 30
Study: 12957685

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Low HOMA-S
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Low IGFBP-1
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: CRP increase
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: High CRP, low IGF-I, low IGFBP-1
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity in obese subjects
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity in non-obese subjects
Number of subjects: 440
Study: 11037041

Group type: EXPERIMENTAL
Intervention: Distinctive words with varying character sizes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distinctive words surrounded by a frame (close or far distance)
Number of subjects: 0